The Journal of Experimental Medicine
VISIT JCB ONLINE!
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 17 December 2001. doi:10.1084/jem.194.12.1789
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jahng, A. W.
Right arrow Articles by Kumar, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jahng, A. W.
Right arrow Articles by Kumar, V.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2001/12/1789/ $5.00
The Journal of Experimental Medicine, Volume 194, Number 12, December 17, 2001 1789-1799


Original Article

Activation of Natural Killer T Cells Potentiates or Prevents Experimental Autoimmune Encephalomyelitis

Alex W. Jahng1, Igor Maricic1, Brian Pedersen1, Nicolas Burdin2, Olga Naidenko2, Mitchell Kronenberg2, Yasuhiko Koezuka3 and Vipin Kumar1

1 Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121
2 Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121
3 Pharmaceutical Research Laboratory, Kirin Brewery Company Limited, Takasaki-shi, Gunma 37012, Japan

Address correspondence to Dr. Vipin Kumar, Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, 10355 Science Center Dr., San Diego, CA 92121. Phone: 858-678-4564; Fax: 858-558-3525; E-mail: vipink{at}liai.org

Natural killer (NK) T cells recognize lipid antigens in the context of the major histocompatibility complex (MHC) class 1–like molecule CD1 and rapidly secrete large amounts of the cytokines interferon (IFN)-{gamma} and interleukin (IL)-4 upon T cell receptor (TCR) engagement. We have asked whether NK T cell activation influences adaptive T cell responses to myelin antigens and their ability to cause experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. While simultaneous activation of NK T cells with the glycolipid {alpha}-galactosylceramide ({alpha}-GalCer) and myelin-reactive T cells potentiates EAE in B10.PL mice, prior activation of NK T cells protects against disease. Exacerbation of EAE is mediated by an enhanced T helper type 1 (Th1) response to myelin basic protein and is lost in mice deficient in IFN-{gamma}. Protection is mediated by immune deviation of the anti-myelin basic protein (MBP) response and is dependent upon the secretion of IL-4. The modulatory effect of {alpha}-GalCer requires the CD1d antigen presentation pathway and is dependent upon the nature of the NK T cell response in B10.PL or C57BL/6 mice. Because CD1 molecules are nonpolymorphic and remarkably conserved among different species, modulation of NK T cell activation represents a target for intervention in T cell–mediated autoimmune diseases.

Key Words: NK T cells • CD1d • experimental autoimmune encephalomyelitis • immunotherapy • {alpha}-galactosylceramide


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS